The capital infusion is earmarked for a broad array of corporate objectives, including product development, strategic partnerships, and the acquisition of new intellectual property. Scilex, which specializes in treatments for acute and chronic pain alongside neurodegenerative and cardiometabolic diseases, intends to use the funds to scale its internal operations and market reach. The transaction remains subject to customary closing conditions before it can be finalized.